Tesamorelin is a synthetic peptide used to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is available under the brand name Egrifta and comes in two different formulations: the daily-dose Egrifta SV and the weekly-reconstituted Egrifta WR. Because these formulations have distinct properties, their storage requirements are not the same. Improper storage, such as refrigeration when not needed or failing to refrigerate when required, can compromise the medication's integrity and effectiveness. This guide provides a detailed overview of the storage protocols for each version, based on manufacturer and official medical information.
Storing Egrifta SV (Single-Use Vial)
The Egrifta SV formulation is a powder that must be reconstituted with sterile water for each daily injection. This version of the medication has strict storage requirements for both the unmixed vials and the reconstituted solution.
Egrifta SV Unreconstituted (Powder Vials)
The powdered vials of Egrifta SV must be stored in the refrigerator between 2°C and 8°C (36°F and 46°F). It is essential to keep the vials in their original packaging to protect them from light until they are ready for use. The diluent (sterile water for injection) provided with Egrifta SV can be stored separately at room temperature. Under no circumstances should the tesamorelin powder vials be frozen, as this will damage the medication.
Egrifta SV Reconstituted (Mixed Solution)
Egrifta SV is a single-use vial, meaning the solution must be used immediately after mixing. Once the powder is mixed with the diluent, the solution is only stable for a short time. Any reconstituted solution that is not used right away must be discarded. Do not save or refrigerate any leftover mixed solution. Proper disposal of unused medication and sharps is crucial for patient safety.
Storing Egrifta WR (Weekly-Reconstituted Vial)
The Egrifta WR formulation is a newer, concentrated version designed for weekly mixing. This eliminates the need for daily mixing, offering a different set of storage protocols.
Egrifta WR Unreconstituted (Powder Vials)
Unlike the older SV version, the powdered vials of Egrifta WR are stored at room temperature, between 20°C and 25°C (68°F and 77°F). As with Egrifta SV, the vials must be kept in their original packaging to protect them from light and should never be frozen. The diluent for Egrifta WR is also kept at room temperature.
Egrifta WR Reconstituted (Mixed Solution)
Once Egrifta WR is mixed, it is stable for up to 7 days, allowing for daily injections from the same vial. During this 7-day period, the reconstituted vial should be kept at room temperature (20°C to 25°C) and protected from light. At the end of the 7-day period, any remaining reconstituted solution must be discarded.
General storage precautions for tesamorelin
Regardless of the formulation, several general precautions should be observed when handling and storing tesamorelin and its components:
- Do not freeze: Freezing any form of tesamorelin can destroy the medication.
- Protect from light: Keep all tesamorelin vials in their original packaging until use to protect them from light exposure.
- Keep out of reach of children and pets: Store all medication and sharps securely to prevent accidental exposure.
- Inspect visually: Always check the reconstituted solution for discoloration or particles before injecting. It should be clear and colorless.
- Dispose of sharps properly: Used needles and syringes should be placed in a designated sharps container.
- Rotate injection sites: This helps prevent skin problems and irritation at the injection site.
Comparison of Egrifta SV and Egrifta WR Storage
| Feature | Egrifta SV | Egrifta WR |
|---|---|---|
| Unreconstituted Vials | Requires Refrigeration (2°C–8°C) | Room Temperature (20°C–25°C) |
| Diluent Vials | Room Temperature | Room Temperature |
| Mixing Frequency | Daily, before each injection | Once per week |
| Reconstituted Storage | Must be used immediately; discard unused portion | Room Temperature for 7 days; discard after |
| Freezing | Do Not Freeze | Do Not Freeze |
| Light Protection | Store in original carton until use | Store in original carton until use |
Conclusion
Whether tesamorelin should be refrigerated depends entirely on the specific product formulation. Egrifta SV vials, which are mixed daily, must be refrigerated before reconstitution, and the leftover mixed solution should be discarded immediately. Conversely, the weekly-reconstituted Egrifta WR vials are kept at room temperature both before and after mixing for their 7-day stability period. Always follow the instructions provided by your healthcare professional and the manufacturer's packaging. Understanding these distinct storage requirements is critical for ensuring the medication's efficacy and safety throughout the course of treatment. If you are ever unsure about how to store or handle your tesamorelin, contact your pharmacist or doctor for clarification.
Important Safety Information
It is vital to consult with your doctor or pharmacist for a complete understanding of your tesamorelin prescription and its handling. Never share needles or syringes with anyone, and always dispose of used supplies in a puncture-resistant container. For detailed information on the risks and benefits of tesamorelin, refer to the official prescribing information from the manufacturer and trusted medical sources.
Authoritative Link
For additional professional information on tesamorelin, including full prescribing details, you can visit the official FDA resource: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf. This link provides access to the most up-to-date label for Egrifta SV.
